Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Cordlife Group ( (SG:P8A) ) is now available.
Cordlife Group Limited is facing legal claims from a group of clients, represented by an individual claimant, alleging negligence and breach of contract in the storage of 109 cord blood units. The claimants are seeking damages amounting to at least S$5,450,000, based on the market value of the damaged units. This legal development follows earlier demands and highlights ongoing challenges for the company in maintaining its operational integrity and client trust.
The most recent analyst rating on (SG:P8A) stock is a Hold with a S$0.16 price target. To see the full list of analyst forecasts on Cordlife Group stock, see the SG:P8A Stock Forecast page.
More about Cordlife Group
Cordlife Group Limited, registered in Singapore, operates in the healthcare industry, specializing in the storage and preservation of cord blood units (CBUs). The company focuses on providing services related to the storage of these biological materials, which are crucial for potential future medical treatments.
Average Trading Volume: 44,422
Technical Sentiment Signal: Strong Sell
Current Market Cap: S$40.85M
Find detailed analytics on P8A stock on TipRanks’ Stock Analysis page.